|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Actelion Ltd., of Allschwil, Switzerland, reported initial positive results from a dose-optimization study evaluating Veletri (tezosentan), an intravenous dual endothelin receptor antagonist, in patients suffering from acute heart failure. Hemodynamic effects were achieved at doses of 5 mg/h and 25 mg/h. The primary endpoint of the study, improvement of cardiac index, was statistically significant for both doses. Data also showed a reduction of pulmonary capillary wedge pressure. The company said it will proceed with a Phase III study based on the results.
Aviva Biosciences Corp., of San Diego, appointed Norrie Russell president and CEO. Russell succeeds Peter ...